SUIC Worldwide Holdings Ltd/ Keyword: Healthcare
SUIC and VisionRenu sign strategic MOU to accelerate expansion in AI biotechnology, precision medicine, and US capital markets
29.06.2026 / 19:04 CET/CEST
The publisher is solely responsible for the content of this announcement.
New York, New York and Taipei, Taiwan – June 29, 2026 (new media wire) – SUIC Worldwide Holdings Ltd. (OTC market: SUIC) (“SUIC”), a technology-enabled investment and business acceleration company; VisionRenu Biomedical Technology Co., Ltd. A Taiwan-based medical technology company specializing in brain health and ophthalmology medical devices (“VisionRenu”) today announced the signing of a strategic memorandum of understanding (MOU). The agreement establishes a framework for cooperation in AI-enabled biotechnology, precision medicine, and international capital markets initiatives, bringing both companies into one of the world’s fastest-growing technology sectors.
Driving global commercialization and capital market expansion
Under this memorandum, SUIC and VisionRenu will combine their respective strengths in medical innovation, commercialization, international business development, and access to U.S. capital markets. The partnership is designed to accelerate VisionRenu’s global expansion while creating long-term value through strategic financing, business development, and potential U.S. capital market opportunities. Both companies see this agreement as a first step toward building a long-term strategic partnership focused on innovation and sustainable growth.
The next wave of AI biotechnology
Artificial intelligence is rapidly reshaping the biotechnology industry by accelerating advances in gene editing, DNA synthesis, precision medicine, and digital biology. AI enables rapid discovery of disease-related genes, improves the accuracy of CRISPR gene editing, optimizes DNA and protein design, and significantly shortens development cycles for next-generation therapeutics. Combined with automated DNA synthesis and robotic laboratories, AI is transforming biological research through design, build, test, learn (DBTL) platforms, creating a new era of intelligent life sciences innovation.
Industry analysts predict that AI-enabled biotechnology will become one of the world’s largest innovation markets in the coming decades, creating multitrillion-dollar opportunities across healthcare, drug discovery, synthetic biology, advanced manufacturing, and sustainable materials.
In line with this global trend, SUIC’s strategic alliance and proposed merger with VisionRenu and partnership with Taiwan’s Ministry of Health and Welfare (MOHW)-backed AI biotech startup will allow the company to expand into this rapidly growing field. By leveraging AI, precision medicine, genetic technology, and international capital market resources, SUIC aims to accelerate innovation while building long-term shareholder value.
About VisionRenu Biomedical Technology Co., Ltd.
VisionRenu Biomedical Technology Co., Ltd. is a Taiwan-based medical technology company focused on researching, developing, manufacturing, and commercializing innovative medical devices for brain health and eye care. The company’s flagship product, the MagRenu® Transcranial Magnetic Stimulation (TMS) System, has been approved by Taiwan’s TFDA for the treatment of depression. The company is also developing proprietary ophthalmic laser technology designed to meet the growing global demand for advanced vision care solutions. If you would like to know more about the company, please click here https://www.vision-renu.com/
About SUIC Worldwide Holdings Co., Ltd.
SUIC Worldwide Holdings Ltd. (OTC Markets: SUIC) is a technology-enabled investment and business acceleration company focused on acquiring and developing innovative businesses with high growth potential. SUIC helps its portfolio companies expand globally and create long-term shareholder value through strategic investments, mergers and acquisitions, and access to international capital markets. Please visit our website. https://sinounitedco.com/
Forward-looking statements
This press release contains forward-looking statements that involve risks and uncertainties. These statements are based on current expectations regarding future events and are subject to a variety of factors that could cause actual results to differ materially from those expressed or implied. The framework agreement announced herein is non-binding and there can be no assurance that a definitive transaction will be completed. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release.
contact
SUIC Worldwide Holdings Co., Ltd.
News release department
Phone: (929) 391-2550
News source: SUIC Worldwide Holdings Ltd
June 29, 2026 Distribution of company news by CET/CEST EQS News – Service of EQS Group.
The publisher is solely responsible for the content of this announcement.
EQS distribution services include regulatory announcements, financial/corporate news, and press releases.
| language: | English |
| company: | SUIC Worldwide Holdings Co., Ltd. |
| US | |
| Ishin: | US8293542085 |
| EQS News ID: | 2356326 |
| end of news | EQS News Service |
2356326 June 29, 2026 CET/CEST
Storing the news in databases or transmitting the news to third parties in a commercial context or for commercial purposes is only permitted with the prior written consent of EQS Group AG.
